DeCure for Immunodeficiency 106, susceptibility to viral infections
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency 106, susceptibility to viral infections — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency 106, susceptibility to viral infections maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency 106, susceptibility to viral infections is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interferon alpha and beta receptor subunit 1 (IFNAR1) — IFNAR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3SE4 · 3.5001 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2007 London clinic study followed 2,386 sexually infected HIV patients from 1999 to 2004. Among them, 63.1% were homosexual men, 4.3% white heterosexual men, 5.1% white heterosexual women, 10.2% black African or other ethnicity heterosexual men, and 17.3% black African or other ethnicity heterosexual women. CD4 count at first visit was highest in homosexual men and lowest in black African heterosexual men. Over the period, antiretroviral therapy use rose from 61.9% to 75.5%. The proportion of patients with a CD4 count of 200/microL or less fell from 19.6% to 9.0%. Among those on ART, viral load above 50 copies/mL dropped from 36.9% to 14.5%; among those on ART for at least 24 weeks, it dropped from 31.2% to 10.1%. Demographic differences persisted: homosexual men had the best outcomes, black African heterosexual men the worst, especially for low CD4 count. Women showed no consistent demographic variation. All groups improved at similar rates.
A 2007 review notes that more than 20 drugs from four classes were available for HIV management by that year, with two new drug classes expected for approval in mid-to-late 2007. It states that combination therapy can lead to durable and perhaps indefinite suppression of viral replication. A 1986 article titled "Treatment of Infections in Patients With the Acquired Immunodeficiency Syndrome" is listed but provides no data, results, or specific drug names in the available text. A 1989 personal view summarises US national cooperative AIDS trials and expresses concern about oversimplification of treatment issues in public policy, but gives no concrete numbers or outcomes.
No abstract in this set reports a controlled trial of a specific drug for immunodeficiency 106 or susceptibility to viral infections. The 2007 London study describes real-world improvements in CD4 count and viral load suppression with routine antiretroviral therapy, but does not address the rare genetic condition immunodeficiency 106. The 2007 review and the 1986 and 1989 pieces offer no patient-level data for that disease. What is missing is any trial or case series specifically enrolling patients with immunodeficiency 106, any funding for such a study, and any stratification of patients by the underlying genetic defect.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Infectious Diseases · 1994 · 71 citations
The Individual Microbiologic Effect of Three Antimycobacterial Agents, Clofazimine, Ethambutol, and Rifampin, on Mycobacterium avium Complex Bacteremia in Patients with AIDS
AbstractThe individual antibacterial activities of clofazimine, ethambutol, and rifampin in the treatment of Mycobacterium avium complex bacteremia in patients with AIDS were determined. Sixty human immunodeficiency virus 1-infected patients who had at least one blood culture positive for M. avium complex were randomized to receive either clofazimine (200 mg), ethambutol (15 mg/kg), or rifampin (600 mg) once daily for 4 weeks. Only ethambutol resulted in a statistically significant reduction in the level of mycobacteremia. The median change in individual baseline colony counts was -0.60 log10 cfu/mL after 4 weeks of ethambutol (P = .046). In contrast, median changes in individual baseline colony counts were -0.2 log10 cfu/mL and +0.2 log10 cfu/mL for clofazimine and rifampin, respectively (both, P > .4). Ethambutol had greater antibacterial activity, as determined by changes in the level of mycobacteremia, than either rifampin or clofazimine, supporting its continued use in combination with other agents in the treatment of M. avium infection.
Archives of Internal Medicine · 2007 · 43 citations
Success of Clinical Care for Human Immunodeficiency Virus Infection According to Demographic Group Among Sexually Infected Patients in a Routine Clinic Population, 1999 to 2004
AbstractBACKGROUND: The success of clinical care for human immunodeficiency virus infection may vary across demographic groups, because of patient- and health care-related factors. METHODS: A total of 2386 patients sexually infected with the human immunodeficiency virus were seen in a London clinic from July 1, 1999, to December 31, 2004. We examined demographic variation and trends over time in the prevalence of the following: (1) a CD4 cell count of 200/microL or less; (2) a viral load of greater than 50 copies/mL among patients receiving antiretroviral therapy (ART); and (3) a viral load of greater than 50 copies/mL among patients receiving ART for 24 weeks or longer. RESULTS: Subjects were homosexual men (63.1%), white heterosexual men (4.3%) and women (5.1%), and black African or other ethnicity heterosexual men (10.2%) and women (17.3%). The CD4 cell count at the first clinic visit was highest among homosexual men and lowest among black African heterosexual men. From 1999 to 2004, ART use increased from 61.9% to 75.5%. The prevalence of a CD4 cell count of 200/microL or less decreased from 19.6% to 9.0%. The prevalence of a viral load of greater than 50 copies/mL decreased from 36.9% to 14.5% among patients receiving ART, and from 31.2% to 10.1% among patients receiving ART for 24 weeks or longer. Demographic variation in the prevalence of each outcome was apparent among men throughout the period: homosexual men had the most favorable profile, and black African heterosexual men had the least favorable profile. Differences were much greater for low CD4 cell count than for raised viral load while receiving ART. There was no consistent demographic variation among women. Favorable trends over time occurred within each demographic group, and were as strong among black African patients as among other subgroups. CONCLUSIONS: The success of clinical care for human immunodeficiency virus infection increased substantially from 1999 to 2004 in this routine clinic population. All demographic subgroups benefited from improvements, despite ongoing differences in the prevalence of immunosuppression.
Protease Inhibitors as Immunomodulatory Drugs for HIV Infection
AbstractMore than 20 drugs from four therapeutic drug classes are widely available for the management of human immunodeficiency virus (HIV) infection, with promising drugs from two new drug classes expected to be approved by the US Food and Drug Administration (FDA) in mid-to-late 2007 (Table 1). When used in combination, these drugs can lead to durable and perhaps indefinite suppression of viral replication. Clinical Pharmacology & Therapeutics (2007) 82, 248–250. doi:10.1038/sj.clpt.6100205
The Journal of Infectious Diseases · 1989 · 3 citations
A Personal View of Efforts in Treatment of Human Immunodeficiency Virus Infection in 1988
AbstractThis presentation summarizes the US national cooperative trials for AIDS treatment and some specific efforts in the treatment of viral infections. The underlying principles behind clinical efforts in the control of the human immunodeficiency virus are described to date. In addition, concerns are voiced regarding the oversimplification of treatment issues presented in the public policy area; some will clearly require responses from interested and informed clinical scientists.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
